WADA’s 2024 Prohibited List now in force

Agency calls on athletes, entourage, and all stakeholders to note major modification concerning tramadol  

The World Anti-Doping Agency (WADA) wishes to remind stakeholders that the 2024 List of Prohibited Substances and Methods (List) and the 2024 Monitoring Program enter into force today (1 January 2024). The 2024 List was approved by WADA’s Executive Committee (ExCo) during its meeting on 22 September 2023 and was first published on 28 September 2023. 

The List is one of the eight International Standards that are mandatory for all Signatories of the World Anti-Doping Code (Code). It designates what substances and methods are prohibited both in- and out-of-competition and which substances are banned in particular sports. 

Major Modifications for 2024 

All Major Modifications for 2024 are outlined in the 2024 Summary of Major Modifications and Explanatory Notes, including the following particular information regarding tramadol:  

On 23 September 2022, the ExCo endorsed the recommendation by WADA’s List Expert Advisory Group (EAG) to prohibit the narcotic tramadol in competition, effective 1 January 2024. The delay in implementation was to ensure stakeholders had enough time to learn and adapt to this change, especially as it pertained to the education of athletes, their entourage, and medical personnel. 

Tramadol has been on WADA’s Monitoring Program and data gathered through that program have indicated significant use in sports. Tramadol abuse, with its risk of physical dependence, opiate use disorder and overdoses, is of concern worldwide and has led to it being a controlled drug in many countries. Research studies funded by WADA, as referenced in the Explanatory Note, have also confirmed the potential for tramadol to enhance sports performance. 

Annual List Review Process 

WADA leads an annual revision process concerning the List, beginning with an initial meeting in January and concluding with the publication of the List by 1 October. This is an extensive consultation process that includes WADA’s List EAG gathering information, including the latest scientific and medical research, trends, and intelligence gathered from law enforcement and pharmaceutical companies; circulating a draft List among stakeholders; and, taking their submissions into consideration to revise the draft, followed by review by the Agency’s Health, Medical and Research (HMR) Committee. The HMR Committee then makes its recommendations to WADA’s ExCo, which approves the List during its September meeting. 

For a substance or method to be added to the List, it must be determined that it meets at least two of the following three criteria: 

1. It has the potential to enhance or enhances sport performance 
 
2. It represents an actual or potential health risk to athletes 
 
3. It violates the spirit of sport 

The full 2024 List was published on 28 September 2023, giving more than three months’ notice to athletes, their entourage, and other stakeholders, enabling them to acquaint themselves with any modifications. Ultimately, athletes are responsible for prohibited substances found in their bodies and prohibited methods found to have been used. Athletes’ entourages are also liable for Anti-Doping Rule Violations if determined to be complicit. Consequently, if there is any doubt as to the status of a substance or method, it is important that they contact their respective Anti-Doping Organizations (International Federation or National Anti-Doping Organization) for advice. 

Therapeutic Use Exemption Program 

It should be noted that for athletes who have a legitimate medical reason for using a prohibited substance or method that is on the List, they can apply for a Therapeutic Use Exemption (TUE) to determine whether they meet the criteria outlined in the International Standard for Therapeutic Use Exemptions (ISTUE). The TUE Program is a rigorous and necessary part of elite sport which has overwhelming acceptance from athletes, physicians, and anti-doping stakeholders.  

Educational Resources 

In addition to the documents linked above, WADA has provided, or will provide, a number of educational resources as part of its Code Implementation Support Program (CISP). These resources can be accessed through the links below and on the Agency’s Anti-Doping Education and Learning Platform (ADEL) and include:  

• A CISP Checklist – Implementing Revised List (available now - originally published January 2021) 

• Athlete and Athlete Support Personnel (ASP) Factsheet on tramadol (available now)  

• Medical Professionals Factsheet on tramadol (available now)  

• Athlete and ASP Guide to the 2024 List (to be available in January 2024)  

Languages and Formats 

The 2024 List, the 2024 Summary of Modifications and Explanatory Notes, and the 2024 Monitoring Program are available for download on WADA’s website in English, French, and Spanish. The list is also available in Arabic, German, Greek, Portuguese, and Turkish. 

Stakeholders wishing to translate the List into other languages are kindly asked to signal their interest to This email address is being protected from spambots. You need JavaScript enabled to view it.. WADA will then provide the necessary files and, once the translation is finalized, will make the translated List available on the Agency’s website.  

The List’s mobile-friendly digital edition is now available.  

WADA Prohibited List for 2024 confirmed, tramadol banned in-competition

As we approach the final stages of the 2023 tour season, the ITIA is reminding players and their support teams to be aware of upcoming changes to the WADA [World Anti-Doping Agency] Prohibited List, which will take effect from 1 January 2024. 
 
The full list of prohibited substances has been published by WADA and is available here. The most notable change to the list is the addition of tramadol, a well-known and commonly used pain-killing drug. Tramadol will become a prohibited substance in the new year, following recommendation of the List Expert Advisory Group to prohibit its use in competition from 2024. 
 
Tramadol has been on the WADA Monitoring Program and data gathered through that programme have indicated significant use in sports. Tramadol abuse, with its dose-dependent risks of physical dependence, opiate addiction and overdoses in the general population, is of concern and has led to it being a controlled drug in many countries. Research studies funded by WADA have also confirmed the potential for tramadol to enhance sports performance. 
 
The ITIA will work with everyone on the tennis tour to ensure that players understand the changes to the WADA Prohibited List in 2024. Players who currently use tramadol as part of their pain management regimen are urged to phase out its use as soon as possible, as its presence in a player’s system will constitute a breach of the Tennis Anti-Doping Programme (TADP) from January 2024 – except in the cases in which a player successfully applies for a Therapeutic Use Exemption (TUE), with legitimate medical grounds for use. 
 
Committed to prioritising prevention of Anti-Doping Rule Violations (ADRVs) over punishment, the ITIA will – in collaboration with the ATP, WTA, and ITF - deliver a mixture of direct communication, education sessions and visual reminders in player-facing areas at tournaments to ensure that players are fully aware of the changes ahead of the 2024 season. 
 
Nicole Sapstead, the ITIA’s Senior Director for Anti-Doping, said: “It is essential that all players and their representatives are aware of upcoming changes to the Prohibited List. In particular, players must note the addition of tramadol as a banned substance from next year. 
 
“As a sport, we have a collective responsibility to ensure that the non-essential use of tramadol is eliminated before the changes to the Prohibited List take effect. 
 
“Being unaware of changes to the list is, unfortunately, no defence against prospective sanctions, and it is incumbent upon the entire tennis family to protect players from unintentional doping violations by taking a proactive approach to rule changes.” 
 
Players seeking further understanding of the WADA Prohibited List, or seeking practical support from the ITIA on anti-doping matters, can make contact with us directly via our app, through direct message on social media, or by filling out the contact form at itia.tennis. 

WADA issues further tramadol guidance for players, support teams and medical personnel

Following publication of the World Anti-Doping Agency [WADA] Prohibited List for 2024, which includes the banning of well-known pain-killer tramadol from in-competition use, further guidance has been provided to assist players, support teams and medical personnel with the upcoming changes.

WADA has issued fact sheets for both players and medical personnel to help prepare them for the 2024 season. These fact sheets have been distributed to medical personnel and the relevant tour bodies, but can be summarised by the following five key points:

1. From 1 January 1 2024,  tramadol will be added to the S7 (narcotics) category of the WADA Prohibited List . This means it will be banned in competition only.

2. Tramadol is an opioid that is used to treat moderate to severe pain. Recent scientific research has suggested that it can also have performance-enhancing effects. Moreover, it is highly addictive, which poses a health risk to athletes.

3. If a player’s physician prescribes tramadol to use incompetition to treat a diagnosed medical condition, players must apply for a Therapeutic Use Exemption (TUE) before they start taking the medication.

4. If players use tramadol within 24 hours before the start of the in-competition period, there is a risk that a sample collected in-competition will return a positive finding.

5. If players use tramadol more than 24 hours before the in-competition period, it is unlikely, but not impossible, that an in-competition test result will be positive.

To download the fact sheets, click here (athletes’ guidance) or here (medical professionals' guidance).

The ITIA remains committed to supporting members of the tennis community – whether they are players, representatives, support staff, coaches, or medical personnel – in understanding all elements of the Tennis Anti-Doping Programme and WADA Prohibited List.

Players seeking further understanding of the WADA Prohibited List, or seeking practical support from the ITIA on anti-doping matters, can make contact with us directly via our app, through direct message on social media, or by filling out the contact form at itia.tennis/contact.